Skip to main content

Table 1 Rapid development of P. yoelii resistance to atovaquone and pyrimethamine

From: Within-host selection of drug resistance in a mouse model of repeated interrupted treatment of Plasmodium yoelii infection

Drugs (mg kg−1 BW)

Isolates

Days of treatment-recovery

Cycles to resistancea

1

2

3

4

5

6

7

Atovaquone (1.44)

PyASN1

1-3

1-2

6-•

    

3

PyASN2

1-5

1-5

1-3

5-•

   

4

PyASN3

1-4

1-3

6-•

    

3

PyASN4

1-4

1-5

3-2

4-•

   

4

PyASN5

1-8

2-2

1-1

1-1

4-•

  

5

PyASN6

1-2

1-5

4-•

    

3

PyASN7

1-3

1-1

6-•

    

3

PyASN8

1-3

1-1

6-•

    

3

PyASN9

1-2

1-3

4-•

    

3

PyASN10

1-5

3-2

7-•

    

3

Atovaquone (0.1)

PyASN11

4-6

9-•

     

2

Atovaquone (0.3)

PyASN12

4-3

10-•

     

2

PyASN13

4-3

12-•

     

2

Atovaquone (0.03)

PyASN14

13-•

      

1

PyASN15

14-•

      

1

Atovaquone (0.01)

PyASN16

12-2

8-•

     

2

Pyrimethamine (0.15)

PyPSN1

1-11

1-24

1-2

2-4

3-3

2-2

2-•

7

PyPSN2

1-5

1-24

3-2

6-3

3-•

  

5

PyPSN3

1-12

1-10

1-3

6-2

4-•

  

5

PyPSN4

1-4

1-26

2-2

3-3

3-•

  

5

PyPSN5

1-11

1-10

1-3

2-2

2-•

  

5

  1. aOne cycle consists of days of treatment (to bring parasitaemia level down to below 0.4%)—days of recovery (to bring parasitaemia level up to return to 3–5%). • = termination of treatment cycles due to the development of stable resistance (parasitaemia level >25%). In the case of PyASN14 and PyASN15, the development of resistance occurred in less than one cycle of treatment
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us